Enanta/$ENTA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Enanta
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Ticker
$ENTA
Sector
Primary listing
Employees
120
Headquarters
Website
Enanta Metrics
BasicAdvanced
$425M
-
-$3.84
1.00
-
Price and volume
Market cap
$425M
Beta
1
52-week high
$15.34
52-week low
$4.09
Average daily volume
308K
Financial strength
Current ratio
4.208
Quick ratio
4.031
Long term debt to equity
258.356
Total debt to equity
310.67
Interest coverage (TTM)
-11.11%
Profitability
EBITDA (TTM)
-80.763
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-125.36%
Operating margin (TTM)
-130.65%
Effective tax rate (TTM)
1.99%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
-16.23%
Return on equity (TTM)
-84.63%
Valuation
Price to revenue (TTM)
4.811
Price to book
4.87
Price to tangible book (TTM)
4.87
Price to free cash flow (TTM)
-9.77
Free cash flow yield (TTM)
-10.24%
Free cash flow per share (TTM)
-1.508
Growth
Revenue change (TTM)
-3.42%
Earnings per share change (TTM)
-29.99%
3-year revenue growth (CAGR)
-8.82%
10-year revenue growth (CAGR)
-8.62%
3-year earnings per share growth (CAGR)
-13.40%
10-year earnings per share growth (CAGR)
-0.63%
What the Analysts think about Enanta
Analyst ratings (Buy, Hold, Sell) for Enanta stock.
Enanta Financial Performance
Revenues and expenses
Enanta Earnings Performance
Company profitability
Enanta News
AllArticlesVideos
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
Business Wire·4 weeks ago
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
Business Wire·2 months ago
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Enanta stock?
Enanta (ENTA) has a market cap of $425M as of December 13, 2025.
What is the P/E ratio for Enanta stock?
The price to earnings (P/E) ratio for Enanta (ENTA) stock is 0 as of December 13, 2025.
Does Enanta stock pay dividends?
No, Enanta (ENTA) stock does not pay dividends to its shareholders as of December 13, 2025.
When is the next Enanta dividend payment date?
Enanta (ENTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Enanta?
Enanta (ENTA) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.